Tourette B-NEG
Disorder I-NEG

-DOCSTART- O

thicken O
the O
intestine B-DNP
and O
stomach B-DNP

-DOCSTART- O

To O
relieve O
cough B-NEG
and O
promote O
expectoration B-NEG
, O
to O
promote O
digestion B-NEU
and O
remove O
stagnancy B-NEG
of I-NEG
food I-NEG
, O
and O
to O
promote O
blood B-NEU
circulation I-NEU
and O
remove O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

malaria B-NEG
; O

malarial B-NEG
disorder I-NEG
malaria B-NEG
and O
other O
disease B-NEG
characterized O
by O
intermittent O
rigor B-NEG
, O
high O
fever B-NEG
and O
sweating B-NEU
. O

-DOCSTART- O

Reserpine's O
mechanism O
of O
action O
is O
through O
inhibition O
of O
the O
ATP/Mg2+ O
pump O
responsible O
for O
the O
sequestering O
of O
neurotransmitters B-DNP
into O
storage O
vesicles O
located O
in O
the O
presynaptic B-DNP
neuron I-DNP
. O
Trichlormethiazide O
appears O
to O
block O
the O
active O
reabsorption O
of O
chloride O
and O
possibly O
sodium O
in O
the O
ascending O
loop B-DNP
of I-DNP
Henle I-DNP
, O
altering O
electrolyte O
transfer O
in O
the O
proximal B-DNP
tubule I-DNP
. O

-DOCSTART- O

deficiency B-NEG
and I-NEG
cold I-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
stomach I-NEG
; O
hypofunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
with O
cold B-NEG
manifestations O

-DOCSTART- O

BACKGROUND O
_ O
AIMS O
: O
Chemotherapy O
with O
an O
anticancer O
agent O
generally O
causes O
gastrointestinal O
tract O
disorders B-NEG
such O
as O
vomiting B-NEG
and O
anorexia B-NEG
, O
but O
the O
mechanism O
remains O
unclear O
. O

Rikkunshito O
, O
a O
kampo O
preparation O
, O
is O
known O
to O
alleviate O
such O
adverse O
reactions O
. O

In O
this O
study O
, O
we O
attempted O
to O
clarify O
the O
mechanism O
. O

METHODS O
: O
We O
investigated O
the O
decreases O
of O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
caused O
by O
cisplatin O
, O
serotonin B-DNP
( O
5-HT B-DNP
) O
, O
5-HT O
agonists O
, O
and O
vagotomy O
as O
well O
as O
the O
decrease-suppressing O
effects O
of O
rikkunshito O
and O
5-HT O
antagonists O
. O

In O
addition O
, O
binding O
affinities O
of O
rikkunshito O
components O
were O
determined O
in O
receptor-binding O
assays O
using O
5-HT2B O
and O
5-HT2C O
receptors O
. O

RESULTS O
: O
Cisplatin O
, O
5-HT B-DNP
, O
BW723C86 O
( O
5-HT2B-receptor O
agonist O
) O
, O
and O
m-chlorophenylpiperazine O
HCl O
( O
5-HT2C O
agonist O
) O
markedly O
decreased O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
levels I-NEU
, O
although O
5-HT3 O
and O
5-HT4 O
agonists O
had O
no O
effect O
. O

In O
contrast O
, O
5-HT2B O
and O
5-HT2C O
antagonists O
suppressed O
the O
cisplatin-induced O
decrease O
of O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
. O

Administration O
of O
rat O
ghrelin B-DNP
improved O
the O
cisplatin-induced O
decrease O
in O
food O
intake O
. O

Vagotomy O
decreased O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
, O
which O
was O
decreased O
further O
by O
cisplatin O
. O

Rikkunshito O
suppressed O
such O
cisplatin-induced O
decreases O
of O
plasma B-NEU
acylated- I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
. O

The O
suppressive O
effect O
of O
rikkunshito O
was O
blocked O
by O
a O
ghrelin O
antagonist O
. O

Components O
of O
rikkunshito O
, O
3,3',4',5,6,7,8-heptamethoxyflavone O
, O
hesperidin O
, O
and O
iso-liquiritigenin O
showed O
a O
5-HT2B-antagonistic O
effect O
in O
vitro O
, O
and O
oral O
administration O
of O
rikkunshito O
suppressed O
the O
cisplatin-induced O
decrease O
in O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
. O

CONCLUSIONS O
: O
The O
cisplatin-induced O
decreases O
of O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
are O
mediated O
by O
5-HT2B/2C B-DNP
receptors I-DNP
and O
suppressed O
by O
flavonoids O
in O
rikkunshito O
. O

-DOCSTART- O

Chronic B-NEG
hepatitis I-NEG

-DOCSTART- O

Eye B-DNP
health I-DNP
, O
Eye B-DNP

-DOCSTART- O

For O
clearing O
weakness B-NEG
and O
heat B-NEU

-DOCSTART- O

Secretin O
binds O
to O
the O
secretin O
receptor O
found O
on O
the O
lining O
of O
S O
cells O
in O
the O
duodenum B-DNP
and O
G O
cells O
in O
the O
stomach B-DNP
. O
Binding O
leads O
to O
the O
secrection O
of O
bicarbonate B-DNP
or O
the O
reduction O
of O
the O
secretion O
of O
gastrin B-DNP
. O
Properly O
functioning O
organs O
( O
duodenum O
, O
pancreas B-DNP
and O
stomach B-DNP
) O
should O
be O
responsive O
to O
this O
hormone O

-DOCSTART- O

To O
regulate O
menstruation B-NEU
, O
replenish O
blood B-DNP
and O
regulate O
qi O
to O
relieve O
pain B-NEG
. O

-DOCSTART- O

Measles B-NEG
papules O
with O
complicated O
pneumonia B-NEG
, O
throat B-NEG
erosion I-NEG
. O

-DOCSTART- O

Treament O
of O
unprocessed O
Fructus O
Hordei O
Germinatus O
: O

Anorexia B-NEG
due O
to O
diminished O
function O
of O
the O
spleen O
, O
galactostasis O
. O

Fructus O
Hordei O
Germinatus O
( O
stir-fried O
) O
: O

Indigestion B-NEG
, O
weaning O
a O
baby O
. O

Fructus O
Hordei O
Germinatus O
( O
charred O
) O
: O

Retention B-NEG
of O
undigested O
food O
with O
epigastric B-NEG
distension I-NEG
and O
pain B-NEG
. O

-DOCSTART- O

May O
be O
used O
to O
treat O
primary O
, O
secondary O
or O
tertiary O
hypothyroidism B-NEG
. O
May O
also O
be O
used O
to O
suppress O
thyroid B-DNP
stimulating I-DNP
hormone I-DNP
( O
TSH B-DNP
) O
secretion O
in O
patients O
with O
simple O
( O
nontoxic O
) O
goiter B-NEG
, O
subacute B-NEG
or I-NEG
chronic I-NEG
lymphocytic I-NEG
thyroiditis I-NEG
multinodular I-NEG
goiter I-NEG
, O
and O
in O
the O
management O
of O
thyroid B-NEG
cancer I-NEG
. O
May O
be O
used O
in O
conjunction O
with O
other O
antithyroid O
agents O
to O
treat O
thyrotoxicosis B-NEG
to O
prevent O
goitrogenesis B-NEG
and O
hypothyroidism B-NEG
. O
May O
also O
be O
used O
for O
differential O
diagnosis O
of O
suspected O
mild O
hyperthyroidism B-NEG
or O
thyroid B-DNP
gland I-DNP
autonomy O
. O

-DOCSTART- O

paralysis B-NEG
due O
to O
stroke B-NEG

-DOCSTART- O

irregular O
chills B-NEG
and I-NEG
fever I-NEG

-DOCSTART- O

Pi B-NEG
syndrome I-NEG
due O
to O
pathogenic B-NEG
wind I-NEG
, O
cold B-NEG
and O
damp B-NEU

-DOCSTART- O

nocturnal B-NEG
enuresis I-NEG
and O
frequency B-NEG
of I-NEG
micturition I-NEG

-DOCSTART- O

Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic B-NEG
cancer I-NEG
and O
lymphoma B-NEG
. O

-DOCSTART- O

the O
stagnation B-NEG
of O
Gi O
a O
morbid B-NEG
condition I-NEG
due O
to O
impeded B-NEG
circulation I-NEG
of O
Gi O
that O
leads O
to O
a O
local B-NEG
obstruction I-NEG
, O
manifested O
by O
distension B-NEU
or O
pain B-NEG
in O
the O
affected O
part O
. O

-DOCSTART- O

nourish O
Eum(Yin O
) O
blood B-DNP

-DOCSTART- O

To O
strengthen O
spleen B-DNP
and O
benefit O
qi O
; O
To O
soothe O
liver B-DNP
and O
modulate O
qi O
; O
To O
revitalize O
blood B-DNP
and O
desolve O
stagnation B-NEG

-DOCSTART- O

relax O
tension B-NEU

-DOCSTART- O

Temporomandibular B-NEG
Joint I-NEG
Dysfunction I-NEG

-DOCSTART- O

For O
clearing O
heat B-NEG
and O
removing O
toxic B-NEG
substances I-NEG

-DOCSTART- O

Its O
alcoholic O
extract O
relaxes O
the O
spasm B-NEG
of O
smooth O
muscles O
of O
gastrointestine O
, O
gallbladder O
and O
bronchus. O
. O

-DOCSTART- O

Inhibiting O
the O
excessive O
secretion O
of O
bronchi B-DNP
and O
uterus B-DNP
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

Pregnancy B-NEU

-DOCSTART- O

exogenous O
exogenous B-NEG
febrile I-NEG
disease I-NEG
; O

syndrome O
of O
T'aeyang B-NEG
meridian I-NEG
affected O
by O
the O
wind B-NEG

affection O
by O
cold B-NEG
; O

common B-NEG
cold I-NEG

-DOCSTART- O

protracted O
diarrhea B-NEG
; O
chronic O
diarrhea B-NEG
; O
prolonged O
diarrhea B-NEG

-DOCSTART- O

Diminshing O
the O
toxicity B-NEG
of I-NEG
kanamycin I-NEG
to O
guinea-pig's O
cochlea O
. O

the O
levels O
of O
serum B-DNP
cholesterol I-DNP
and O
triglyceride B-DNP
. O

Hindering O
the O
formation O
of O
arteriosclerotic B-NEG
deposits O
in O
the O
vessels O
. O

-DOCSTART- O

Infant B-NEG
, I-NEG
Diabetic I-NEG
Mother I-NEG

-DOCSTART- O

nourish O
Eum(Yin O
) O
and O
reinforce O
blood B-DNP

-DOCSTART- O

Hypertension B-NEG
, O
kidney B-NEG
vacuity I-NEG
lumbago I-NEG
, O
weakness B-NEG
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O

restlessness B-NEG
and O
thirst B-NEU
; O

polydipsia B-NEG

-DOCSTART- O

Liver O
Transplantation O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Hypersensitivity B-NEG
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

1 O
To O
dispel O
cold B-NEG
and O
stop O
pain B-NEG
; O
2 O
To O
regulate O
qi O
and O
harmonize O
the O
stomach B-DNP

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
motility B-NEU
, O
Others O
, O
Hemostatic B-NEU
function I-NEU

-DOCSTART- O

1 O
Its O
decoction O
can O
lower O
blood B-NEU
pressure I-NEU

2 O
. O
Inhibiting O
the O
growth B-NEU
of I-NEU
(a)-streptococcus I-NEU

3 O
. O
Shortening O
the O
bleeding B-NEG
time O
. O

4 O
. O
Anti-inflammatory B-POS

5 O
. O
Diuretic O
. O

-DOCSTART- O

breast B-NEG
abscess I-NEG
; O
abscess B-NEG
of I-NEG
breast I-NEG
; O
acute B-NEG
mastitis I-NEG

-DOCSTART- O

Red B-NEG
eyes I-NEG
with O
gall O
, O
pulmonary B-NEG
welling I-NEG
abscess I-NEG
, O
diarrhea B-NEG
, O
dysentery B-NEG
, O
leukorrhea B-NEG
, O
postpartum B-NEG
blood I-NEG
stasis I-NEG
abdominal I-NEG
pain I-NEG
, O
indigestion B-NEG
, O
nephritis B-NEG
with O
edema B-NEG
, O
cirrhosis B-NEG
with O
ascites B-NEG
, O
swelling B-NEG
toxin O
of O
welling B-NEG
abscess I-NEG
and O
sore B-NEG
. O

-DOCSTART- O

convulsive B-NEG
disease I-NEG
; O
epilepsy B-NEG
induced O
by O
frightening O

-DOCSTART- O

protracted O
dysentery B-NEG
; O
chronic O
dysentery B-NEG
; O
prolonged O
dysentery B-NEG

-DOCSTART- O

epilepsy B-NEG
induced O
by O
frightening O
and O
mania-withdrawal O

-DOCSTART- O

cool O
blood B-DNP

-DOCSTART- O

white-haired O

-DOCSTART- O

Its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-NEU
circulation. I-NEU
. O

-DOCSTART- O

Treatment O
of O
mass O
in O
the O
abdomen B-DNP
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
abdominal B-NEG
distension I-NEG
and O
pain B-NEG
caused O
by O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
. O

-DOCSTART- O

To O
relieve O
rheumatic B-NEU
conditions I-NEU
, O
to O
strengthen O
the O
tendons B-DNP
and O
bones B-DNP
, O
and O
to O
arrest O
bleeding B-NEG
. O

-DOCSTART- O

OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
analyse O
the O
value O
of O
intraoperative O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
( O
SBB O
) O
. O

So O
far O
, O
only O
a O
few O
studies O
have O
reported O
about O
the O
usefulness O
of O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
. O

METHODS O
: O
Between O
1998 O
and O
2003 O
, O
155 O
SBBs O
were O
performed O
in O
153 O
patients O
with O
micro-Doppler O
( O
81 O
males O
, O
72 O
females O
, O
mean O
age O
: O
59 O
years O
) O
. O

All O
operations O
were O
performed O
using O
a O
ZD-frame O
and O
a O
multiplanar O
computer O
tomography-guided O
trajectory O
planning O
system O
( O
Leibinger O
SPP O
) O
. O

A O
16 O
MHz O
micro-Doppler O
probe O
( O
diameter O
1 O
mm O
, O
DWL O
) O
was O
used O
in O
all O
cases O
to O
explore O
the O
area O
of O
biopsy O
before O
the O
tissue O
probes O
were O
taken O
. O

Serial O
biopsies O
( O
mean O
, O
6 O
samples O
) O
were O
taken O
with O
the O
Sedan O
side-cutting O
cannula O
(n O
= O
145 O
) O
or O
the O
small O
forceps O
(n O
= O
10 O
) O
. O

We O
evaluated O
the O
number O
of O
intraoperative O
detectable O
vessel O
signals O
by O
micro-Doppler O
, O
intraoperative O
bleedings O
as O
well O
as O
bleedings O
detected O
by O
postoperative O
CT O
( O
which O
was O
performed O
in O
all O
cases O
) O
. O

We O
compared O
our O
results O
according O
to O
bleeding O
- O
related O
complications O
with O
the O
data O
of O
stereotactic O
biopsy O
series O
from O
the O
recent O
literature O
. O

RESULTS O
: O
A O
conclusive O
histopathological O
diagnosis O
was O
achieved O
in O
150/153 O
patients O
( O
98 O
% O
) O
. O

A O
re-biopsy O
had O
to O
be O
undertaken O
in O
2 O
cases O
. O

In O
98 O
biopsies O
( O
63 O
% O
) O
, O
no O
vessel O
could O
be O
detected O
with O
the O
micro-Doppler O
. O

In O
the O
remainder O
, O
a O
signal O
of O
arterial O
vessels O
was O
detected O
in O
22 O
( O
14 O
%) O
and O
a O
signal O
of O
venous O
vessels O
in O
35 O
cases O
( O
23 O
% O
) O
. O

Detection O
of O
a O
vessel O
in O
the O
micro-Doppler O
led O
to O
a O
change O
of O
the O
biopsy O
site O
in O
each O
case O
within O
the O
same O
trajectory O
. O

Biopsy-related O
bleedings O
were O
detected O
in O
4 O
cases O
( O
2.6 O
% O
) O
. O

Among O
these O
, O
the O
only O
bleeding B-NEG
which O
occurred O
without O
any O
signs O
of O
vessels B-DNP
in O
the O
micro-Doppler O
happened O
in O
a O
case O
of O
a O
melanoma B-NEG
. O

The O
overall O
biopsy-related O
permanent O
morbidity O
was O
0.6 O
% O
(n O
= O
1 O
) O
. O

The O
biopsy-related O
mortality O
was O
0 O

CONCLUSIONS O
: O
Despite O
the O
overall O
high O
security O
of O
SBB O
, O
the O
use O
of O
intraoperative O
micro-Doppler O
may O
lead O
to O
an O
additional O
reduction O
of O
the O
risk O
for O
a O
biopsy-related O
bleeding O
without O
enormous O
expense O
. O

-DOCSTART- O

Hip B-NEG
Fracture I-NEG

-DOCSTART- O

stranguria B-NEG
due O
to O
heat O
; O

heat-type B-NEG
stranguria I-NEG

-DOCSTART- O

deficiency O
of O
the O
Yang O
of O
the O
spleen O
and O
the O
kidney O

-DOCSTART- O

arthralgia B-NEG
and O
myalgia B-NEG
; O
pain B-NEG
in O
the O
muscles O
and O
bones O

-DOCSTART- O

dispel O
wind B-NEG

-DOCSTART- O

Neuropathic B-NEG
pain I-NEG

-DOCSTART- O

Pneumonia B-NEG
, O
pyothorax B-NEG
, O
sore B-NEG
pharynx I-NEG
, O
oral B-NEG
ulcer I-NEG
, O
vesical B-NEG
calculus I-NEG
, O
swollen O
welling O
abscess B-NEG
. O

-DOCSTART- O

Urinary B-DNP
systems I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP
, O
Liver B-DNP
health I-DNP
, O
Liver B-DNP

-DOCSTART- O

clear O
the O
lung B-DNP

-DOCSTART- O

Tuberculosis B-NEG
, O
weak O
yin O
and O
agitated O
fire O
, O
thin B-NEU
and I-NEU
hot I-NEU
body I-NEU
, O
cough B-NEG
, O
phlegm B-NEG
, O
spitting B-NEG
blood I-NEG
, O
chest B-NEG
pain I-NEG
, O
dry B-NEG
mouth I-NEG
, O
frequent B-NEG
pulse I-NEG

-DOCSTART- O

Propranolol O
competes O
with O
sympathomimetic O
neurotransmitters O
such O
as O
catecholamines O
for O
binding O
at O
beta(1)-adrenergic O
receptors O
in O
the O
heart O
, O
inhibiting O
sympathetic B-NEU
stimulation I-NEU
. O

Hydrochlorothiazide O
, O
a O
thiazide O
diuretic O
, O
inhibits O
water B-NEU
reabsorption I-NEU
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-DNP
symporter I-DNP
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
5% O
of O
total O
sodium B-NEU
reabsorption I-NEU
. O

-DOCSTART- O

resolve O
phlegm B-NEG
and O
relieve O
cough B-NEG

-DOCSTART- O

To O
purge O
pathogenic O
fire O
and O
lessen O
virulence B-NEG
of O
any O
pathogenic O
organism O
. O

-DOCSTART- O

Based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
MR O
) O
instruments O
. O

Paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

When O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

MR O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

MR O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
T1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
T2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

In O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
T1 O
, O
and O
variation O
in O
the O
T2 O
. O

When O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
T1 O
and O
the O
T2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

At O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
T1 B-NEU
relaxation I-NEU
time O
, O
thus O
producing O
an O
increase O
in O
signal B-NEU
intensity I-NEU
. O

Gadodiamide O
does O
not O
cross O
the O
intact B-DNP
blood-brain I-DNP
barrier I-DNP
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-DNP
nervous I-DNP
system I-DNP
( O
CNS B-DNP
) O
lesions O
that O
have O
not O
caused O
an O
abnormal B-DNP
blood-brain I-DNP
barrier I-DNP
( O
e.g O
. O
, O
cysts O
, O
mature O
post-operative O
scars O
) O
. O

Abnormal B-NEG
vascularity I-NEG
or O
disruption B-NEG
of I-NEG
the I-NEG
blood-brain I-NEG
barrier I-NEG
allows O
accumulation O
of O
gadodiamide B-DNP
in I-DNP
lesions I-DNP
such O
as O
neoplasms B-DNP
, O
abscesses B-NEG
, O
and O
subacute B-NEG
infarcts I-NEG
. O

-DOCSTART- O

a O
disease O
that O
difficult O
to O
sleep O
, O
beating O
fast O
in O
the O
chest O
, O
feel O
anxiety B-NEG
, O
sometimes O
frightening B-NEG
well O
due O
to O
cold B-NEG
of O
gallbladder B-DNP
meridian I-DNP

-DOCSTART- O

Used O
mainly O
in O
female O
infertility O
due O
to O
anovulation B-NEG
( O
e.g O
. O
due O
to O
polycystic B-NEG
ovary I-NEG
syndrome I-NEG
) O
to O
induce O
ovulation B-NEU
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
resolve O
toxin B-NEG
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

To O
suppress O
cough B-NEG
and O
calm O
asthma B-NEG
, O
dissipate O
stasis B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Mycophenolate O
stops O
T-cell B-DNP
and I-DNP
B-cell I-DNP
proliferation I-DNP
through O
selective O
inhibition O
of O
the O
de O
novo O
pathway O
of O
purine B-DNP
biosynthesis I-DNP
. O

-DOCSTART- O

prolonged O
chronic B-NEG
headache I-NEG

dead B-NEG
coldness I-NEG
of O
the O
extremities O

morbid B-NEG
condition I-NEG
of O
intense O
pain B-NEG
in O
the O
chest O
and O
abdomen O
, O
sudden O
coldness B-NEG
of O
the O
two O
feet O
, O
restlessness B-NEG
with O
disinclination B-NEG
ti O
eat O
and O
unsmooth O
pulse B-DNP

-DOCSTART- O

hematuria B-NEG
; O
bloody B-NEG
urine I-NEG
without O
pain B-NEG

-DOCSTART- O

Its O
decoction O
promotes O
the O
secretion O
of O
pepsin O
and O
gastric O
juice O
. O

-DOCSTART- O

Used O
for O
the O
treatment O
of O
individual O
patients O
with O
certain O
filarial B-NEG
diseases I-NEG
including O
tropical B-NEG
pulmonary I-NEG
eosinophilia I-NEG
, O
loiasis B-NEG
, O
and O
lymphatic B-NEG
filariasis I-NEG
caused O
by O
infection B-NEG
with I-NEG
Wuchereria I-NEG
bancrofti I-NEG
, I-NEG
Brugia I-NEG
malayi I-NEG
, I-NEG
or I-NEG
Brugia I-NEG
timori I-NEG
. O

-DOCSTART- O

damp-warm B-NEG
disease I-NEG
febrile B-NEG
disease I-NEG
often O
occurring O
around O
mid-summer O
, O
July O
, O
caused O
by O
damp-heat B-NEG
pathogene I-NEG
, O
which O
mainly O
involves O
the O
gastro-intestinal B-DNP
tract I-DNP
often O
in O
a O
protracted O
course O
. O

It O
may O
sometimes O
be O
seen O
in O
diseases O
such O
as O
typhoid B-NEG
fever I-NEG
. O

-DOCSTART- O

Cyclophosphamide's O
active O
metabolites O
aldophosphamide O
and O
phosphoramide O
mustard O
bind O
to O
DNA O
, O
thereby O
inhibiting O
DNA B-NEU
replication I-NEU
and O
initiating O
cell B-NEG
death I-NEG
. O

-DOCSTART- O

Wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
pain B-NEG
in O
stomach O
duct O
, O
hemiplegia B-NEG
, O
gan B-NEG
accumulation I-NEG
, O
dysentery B-NEG
. O

-DOCSTART- O

pectoral B-NEG
pain I-NEG
with O
stuffiness B-NEG
; O
chest B-NEG
impediment I-NEG
; O
chest B-NEG
blockage I-NEG
; O
obstruction O
of O
Gi O
in O
the O
chest O
( O
1 O
) O
a O
morbid B-NEG
condition I-NEG
due O
to O
stagnation O
of O
dampness O
and O
phlegm O
, O
marked O
by O
choking B-NEG
pain I-NEG
in O
the O
chest O
, O
sometimes O
referring O
to O
the O
back B-DNP
, O
usually O
accompanied O
by O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cough B-NEG
. O
( O

2 O
) O
obstruction O
of O
Gi O
in O
the O
stomach O
, O
chest B-NEG
pain I-NEG
that O
occurs O
immediately O
after O
eating O
, O
accompanied O
by O
difficulty B-NEG
in I-NEG
swallowing I-NEG
and O
frequent O
vomiting B-NEG
. O

-DOCSTART- O

To O
clear O
damp B-NEG
heat I-NEG
, O
resolve O
sore O
toxin B-NEG
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Pain B-NEG
Due O
to O
Certain O
Specified O
Procedures O

-DOCSTART- O

Menopausal B-NEG
syndrome I-NEG
marked O
by O
afternoon O
fever B-NEG
, O
excessive B-NEG
sweating I-NEG
, O
dizziness B-NEG
, O
tinnitus B-NEG
, O
insomnia B-NEG
and O
unsteady B-NEG
blood I-NEG
pressure I-NEG
. O

-DOCSTART- O

Relief O
of O
mild O
to O
moderate O
pain B-NEG
of O
acte B-NEG
musculoskeletal I-NEG
disorders I-NEG
. O

-DOCSTART- O

Healthy O

-DOCSTART- O

distribution O
) O
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Strength B-POS
and O
power B-POS
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

The O
role O
of O
crude O
polysaccharide O
fractions O
on O
the O
mitogenic B-NEU
activity I-NEU
by O
Shosaikoto O
. O

-DOCSTART- O

disperse O
accumulation O
and O
relieve O
pain B-NEG

-DOCSTART- O

Blood B-NEG
vaculty I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
amenorrhea B-NEG
, O
postpartum B-NEG
vacuity I-NEG
weakness I-NEG
, O
aching B-NEG
in I-NEG
lumbus I-NEG
and I-NEG
legs I-NEG
, O
fracture B-NEG
due O
to O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

Anti-inflammatory O
activity O
of O
Gumiganghwaltang O
through O
the O
inhibition O
of O
nuclear B-NEU
factor-kappa I-NEU
B I-NEU
activation I-NEU
in O
peritoneal O
macrophages O
. O

-DOCSTART- O

vomiting B-NEG
due O
to O
dysphagia B-NEG

-DOCSTART- O

For O
breaking O
blood B-DNP
and O
desolving O
stasis B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Inflammation B-NEG
, O
Other O
system O
health O
, O
Others O

-DOCSTART- O

anal B-NEG
fistula I-NEG
hemorrhoids I-NEG
complicated O
by O
anal B-NEG
fistula I-NEG
. O

-DOCSTART- O

sores B-NEG
of O
the O
mouth O
or O
tongue O
; O
aphthae B-NEG
and O
boil B-NEG
of O
mouth O
and O
tongue O

-DOCSTART- O

abortion B-NEG

-DOCSTART- O

dry B-NEG
mouth I-NEG
; O

xerostomia B-NEG
; O

dryness B-NEG
of I-NEG
mouth I-NEG

-DOCSTART- O

1 O
flaccidity B-NEG
of I-NEG
lower I-NEG
limbs I-NEG
2 O
leg O
Gi O
; O
beriberi O

-DOCSTART- O

postpartum B-NEG
anemic I-NEG
faintness I-NEG
; O
faint B-NEG
after O
childbirth O

-DOCSTART- O

latent O
summer B-NEG
heat I-NEG
syndrome I-NEG

-DOCSTART- O

This O
is O
an O
external B-NEG
wound I-NEG
in O
muscle O
of O
waist O
. O

-DOCSTART- O

distention O
and O
pain B-NEG
in O
chest O
and O
abdomen O
with O
driving O
up O
Qi O

-DOCSTART- O

stiffness B-NEG
of O
four O
ends O

-DOCSTART- O

Both O
tolterodine O
and O
its O
active O
metabolite O
, O
5-hydroxymethyltolterodine O
, O
act O
as O
competitive O
antagonists O
at O
muscarinic O
receptors O
. O
This O
antagonism O
results O
in O
inhibition O
of O
bladder B-NEG
contraction I-NEG
, O
decrease O
in O
detrusor B-NEG
pressure I-NEG
, O
and O
an O
incomplete B-NEG
emptying I-NEG
of I-NEG
the I-NEG
bladder I-NEG
. O

-DOCSTART- O

Insulin O
glargine O
is O
is O
a O
long-acting O
basal O
insulin O
analogue O
and O
binds O
to O
the O
insulin O
receptor O
, O
the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity I-DNP
intrinsic I-DNP
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

Insulin O
glulisine O
is O
a O
biosynthetic O
, O
rapid-acting O
human O
insulin O
analogue O
which O
differs O
from O
native O
human O
insulin O
in O
that O
the O
amino O
acid O
arginine O
at O
position O
B3 O
is O
replaced O
by O
lysine O
and O
the O
lysine O
at O
position O
B29 O
is O
replaced O
by O
glutamic O
acid O
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
poor B-NEG
appetite I-NEG
, O
vomiting B-NEG
, O
and O
diarrhea B-NEG
due O
to O
various O
reasons O
. O

-DOCSTART- O

Tourette B-DNP
Syndrome I-DNP

-DOCSTART- O

promote O
blood B-DNP
vessel I-DNP

-DOCSTART- O

Taxation B-NEG
damage I-NEG
and O
sinew B-NEG
bone I-NEG
pain I-NEG
, O
impotence B-NEG
, O
stomachache B-NEG
, O
innominate B-NEG
toxin I-NEG
swelling I-NEG
, O
knife B-NEG
wound I-NEG
. O

-DOCSTART- O

Intercritical O
Gout B-NEG

-DOCSTART- O

refers O
to O
the O
heavy O
coughing B-NEG
and O
shortness B-NEG
of I-NEG
breath I-NEG
due O
to O
the O
heat B-NEU
In O
the O
lung B-DNP

-DOCSTART- O

To O
benefit O
qi O
and O
revitalize B-POS
blood I-POS
; O
To O
nourish O
yin O
and O
tonify O
yang O

-DOCSTART- O

Parasite O
worms B-NEG

-DOCSTART- O

The O
antiinflammatory O
effects O
of O
tenoxicam O
may O
result O
from O
the O
inhibition O
of O
the O
enzyme B-DNP
cycooxygenase I-DNP
and O
the O
subsequent O
peripheral O
inhibition O
of O
prostaglandin B-DNP
synthesis I-DNP
. O
As O
prostaglandins O
sensitize O
pain O
receptors O
, O
their O
inhibition O
accounts O
for O
the O
peripheral O
analgesic O
effects O
of O
tenoxicam O
. O
Antipyresis O
may O
occur O
by O
central O
action O
on O
the O
hypothalamus B-DNP
, O
resulting O
in O
peripheral B-NEU
dilation I-NEU
, O
increased O
cutaneous B-NEU
blood I-NEU
flow I-NEU
, O
and O
subsequent O
heat O
loss O
. O

-DOCSTART- O

For O
the O
treatment O
of O
essential B-NEG
hypertension I-NEG
, O
alone O
or O
as O
an O
adjunct O
. O

Also O
for O
the O
management O
of O
severe B-NEG
hypertension I-NEG
when O
the O
drug O
cannot O
be O
given O
orally O
or O
when O
blood B-NEU
pressure I-NEU
must O
be O
lowered O
immediately O
, O
congestive B-NEG
heart I-NEG
failure I-NEG
( O
in O
combination O
with O
cardiac O
glycosides O
and O
diuretics O
and O
/ O
or O
with O
isosorbide O
dinitrate O
) O
, O
and O
hypertension B-NEG
secondary I-NEG
to O
pre-eclampsia B-NEG
/ O
eclampsia B-NEG
. O

-DOCSTART- O

plum-stone B-NEG
syndrome I-NEG
; O
globus B-NEG
hystericus I-NEG
a O
subjective O
sensation O
as O
if O
a O
plum O
pit O
is O
stuck O
in O
the O
throat O
is O
compressed O
. O

-DOCSTART- O

strengthen O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

Treatment O
of O
rheumatic B-NEG
arthritis I-NEG
with O
muscular B-NEG
contracture I-NEG
, O
aching B-NEG
of O
the O
loins O
and O
knees O
, O
inflammation B-NEG
of O
the O
throat O
, O
carbuncle B-NEG
and O
boils B-NEG
, O
traumatic B-NEG
injuries I-NEG
. O

-DOCSTART- O

Chlorambucil O
alkylates O
and O
cross-links O
DNA O
during O
all O
phases O
of O
the O
cell O
cycle O
, O
resulting O
in O
disruption B-NEG
of I-NEG
DNA I-NEG
function I-NEG
, O
cell B-POS
cycle I-POS
arrest I-POS
, O
and O
apoptosis B-POS
. O

-DOCSTART- O

desire B-NEG
for I-NEG
vomiting I-NEG
; O
feel O
nauseated B-NEG
; O
nausea B-NEG

-DOCSTART- O

Hepatitis B-NEG
B I-NEG
Infection I-NEG

-DOCSTART- O

For O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-NEG
associated O
with O
chronic B-NEG
renal I-NEG
failure I-NEG
( O
CRF B-NEG
) O
in O
adult O
and O
paediatric O
patients O
. O

Also O
for O
use O
in O
the O
treatment O
of O
anaemia B-NEG
and O
reduction B-NEG
of I-NEG
transfusion I-NEG
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-NEG
tumours I-NEG
, O
malignant B-NEG
lymphoma I-NEG
or O
multiple B-NEG
myeloma I-NEG
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia O
at O
the O
start O
of O
chemotherapy O
) O
. O

Also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-DNP
blood I-DNP
from O
patients O
in O
a O
predonation O
program O
. O

When O
administered O
subcutaneously O
, O
Epoetin O
Zeta O
is O
equivalent O
to O
Epoetin O
Alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O

Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-NEG
of O
the O
eye O
, O
ulcers B-NEG
in O
the O
mouth O
. O

-DOCSTART- O

dispel O
wind B-NEG
and O
drain O
dampness B-NEU

-DOCSTART- O

The O
functional O
group O
of O
the O
anion O
exchange O
resin O
is O
a O
quaternary O
ammonium O
group O
attached O
to O
an O
inert O
styrene-divinylbenzene O
copolymer O
. O

-DOCSTART- O

rhIGFBP-3 O
is O
a O
protein O
that O
is O
normally O
found O
in O
our O
bloodstream O
that O
has O
been O
shown O
to O
induce O
cancer O
cell O
death O
in O
a O
variety O
of O
experimental O
systems O
. O
Several O
studies O
have O
demonstrated O
that O
cancer B-NEG
risk O
increases O
with O
decreasing O
levels O
of O
circulating O
IGFBP-3 B-DNP
. O
IGFBP-3 B-DNP
can O
induce O
cell O
cycle O
arrest O
and O
enhance O
the O
efficacy O
of O
chemotherapeutic O
agents O
. O

-DOCSTART- O

normalize O
Gi(Qi O
) O
and O
relieve O
pain B-NEG

-DOCSTART- O

1 O
Hypotensive B-NEG
2 O
Promoting O
phagocytosis B-NEU
of I-NEU
mononuclear I-NEU
phagocytes I-NEU
. O

Sedative O
and O
diuretic O
. O

-DOCSTART- O

Kidney B-NEG
disease I-NEG
of O
diabetes O
type O

-DOCSTART- O

Gastric B-NEG
Cancer I-NEG

-DOCSTART- O

Native O
Americans O
residing O
in O
a O
broad O
region O
downwind O
from O
the O
Nevada O
Test O
Site O
during O
the O
1950s O
and O
1960s O
received O
significant O
radiation O
exposures O
from O
nuclear O
weapons O
testing O
. O

Because O
of O
differences O
in O
diet O
, O
activities O
, O
and O
housing O
, O
their O
radiation O
exposures O
are O
only O
very O
imperfectly O
represented O
in O
the O
Department O
of O
Energy O
dose O
reconstructions O
. O

There O
are O
important O
missing O
pathways O
, O
including O
exposures O
to O
radioactive O
iodine O
from O
eating O
small O
game O
. O

The O
dose O
reconstruction O
model O
assumptions O
about O
cattle O
feeding O
practices O
across O
a O
year O
are O
unlikely O
to O
apply O
to O
the O
native O
communities O
as O
are O
other O
model O
assumptions O
about O
diet O
. O

Thus O
exposures O
from O
drinking O
milk O
and O
eating O
vegetables O
have O
not O
yet O
been O
properly O
estimated O
for O
these O
communities O
. O

Through O
consultations O
with O
members O
of O
the O
affected O
communities O
, O
these O
deficiencies O
could O
be O
corrected O
and O
the O
dose O
reconstruction O
extended O
to O
Native O
Americans O
. O

An O
illustration O
of O
the O
feasibility O
of O
extending O
the O
dose O
reconstruction O
is O
provided O
by O
a O
sample O
calculation O
to O
estimate O
radiation O
exposures O
to O
the O
thyroid B-DNP
from O
eating O
radio-iodine-contaminated O
rabbit O
thyroids B-DNP
after O
the O
Sedan O
test O
. O

The O
illustration O
is O
continued O
with O
a O
discussion O
of O
how O
the O
calculation O
results O
may O
be O
used O
to O
make O
estimates O
for O
other O
tests O
and O
other O
locations O
. O

-DOCSTART- O

sore B-NEG
of I-NEG
scrotum I-NEG

-DOCSTART- O

dirty B-NEG
face I-NEG
; O

dirty B-NEG
complexion I-NEG
; O

grimy B-NEG
facial I-NEG
complexion I-NEG
a O
face O
appearing O
as O
if O
covered O
with O
dirt B-NEG
, O
as O
often O
seen O
in O
hepatic B-NEG
disease I-NEG
, O
disease B-NEG
due O
to O
damp-heat B-NEG
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Motivation O
, O
Mood O
, O
Endocrine B-DNP
system I-DNP
, O
effort O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

cool O
blood B-DNP
and O
stop O
dysentery B-NEG

-DOCSTART- O

The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin O
and O
other O
activated O
clotting O
factors O
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization O
of O
fibrinogen O
to O
fibrin O
and O
the O
subsequent O
formation O
of O
clots O
. O

-DOCSTART- O

scrofula B-NEG
; O
tuberculosis B-NEG
of O
the O
cervical O
lymphic O
node O

-DOCSTART- O

function O

-DOCSTART- O

NRP409 O
is O
presumed O
to O
work O
like O
the O
endogenous O
thyroid O
hormone O
thyroxine O
( O
T O
4 O
, O
a O
tetra-iodinated O
tyrosine O
derivative O
) O
. O

In O
the O
liver B-DNP
and O
kidney B-DNP
, O
T O
4 O
is O
converted O
to O
T O
3, O
the O
active O
metabolite O
. O

In O
order O
to O
increase O
solubility O
, O
the O
thyroid O
hormones O
attach O
to O
thyroid O
hormone O
binding O
proteins O
, O
thyroxin-binding O
globulin O
, O
and O
thyroxin-binding O
prealbumin O
( O
transthyretin O
) O
. O

Transport O
and O
binding O
to O
thyroid O
hormone O
receptors O
in O
the O
cytoplasm O
and O
nucleus O
then O
takes O
place O
. O

Thus O
by O
acting O
as O
a O
replacement O
for O
natural O
thyroxine O
, O
symptoms O
of O
thyroxine O
deficiency O
are O
relieved O
. O

-DOCSTART- O

To O
resolve O
phlegm B-NEG
and O
benefit O
throat B-DNP

-DOCSTART- O

Bone B-NEG
Marrow I-NEG
Suppression I-NEG

-DOCSTART- O

Motivation O
, O
Mood O
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Others O
, O
effort O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

Chai O
Hu O
( O
Radix O
Burpleuri O
) O
, O
a O
major O
ingredient O
in O
many O
traditional O
Chinese O
medicine O
formulas O
, O
such O
as O
Xiao O
Yan O
Wan O
, O
is O
used O
in O
the O
treatment O
of O
liver B-DNP
stagnation O
and O
spleen B-DNP
deficiency O
syndrome O
( O
LSSDS O
) O
. O

The O
objectives O
of O
this O
study O
were O
to O
examine O
the O
effects O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
changes B-NEU
of I-NEU
plasma I-NEU
indices I-NEU
in O
patients O
with O
LSSDS O
. O

Fifty-eight O
cases O
of O
LSSDS O
were O
randomly O
divided O
into O
two O
groups O
: O
41 O
cases O
in O
the O
experimental O
group O
were O
treated O
with O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
and O
17 O
cases O
in O
the O
control O
group O
were O
treated O
with O
Zhi O
Bai O
Di O
Huang O
Wan O
for O
one O
consecutive O
month O
in O
a O
single O
blind O
design O
. O

Before O
and O
after O
treatment O
, O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
was O
applied O
to O
determine O
the O
changes B-NEU
of I-NEU
plasma I-NEU
norepinephrine I-NEU
( I-NEU
NE I-NEU
) I-NEU
, I-NEU
epinephrine I-NEU
( I-NEU
E I-NEU
) I-NEU
and I-NEU
dopamine I-NEU
( I-NEU
DA I-NEU
) I-NEU
. O

Radioimmunoassay O
was O
performed O
to O
measure O
the O
amount O
of O
plasma O
beta-endorphin O
( O
beta-EP O
) O
, O
adrenocorticotropin O
hormone O
( O
ACTH O
) O
, O
estradiol O
( O
E2 O
) O
and O
testosterone O
( O
T O
) O
, O
and O
laser O
nephelometry O
was O
also O
conducted O
to O
measure O
plasma O
immunoglobulin O
A O
( O
Ig O
A) O
and O
G O
( O
Ig O
G O
) O
. O

Compared O
to O
baseline O
levels O
, O
plasma B-DNP
beta-EP I-DNP
was O
significantly O
increased O
(p O
< O
0.01 O
) O
, O
while O
E B-DNP
and O
DA B-DNP
were O
markedly O
decreased O
(p O
< O
0.01 O
) O
after O
the O
administration O
of O
Xiao O
Yao O
Wan O
in O
the O
experimental O
group O
. O

The O
other O
indices O
did O
not O
change O
. O

This O
is O
the O
first O
evidence O
showing O
that O
the O
effect O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
treatment O
of O
patients O
with O
LSSDS O
may O
be O
through O
enhancing O
plasma B-DNP
beta-EP I-DNP
and O
decreasing O
E B-DNP
and O
DA B-DNP
release O
. O

We O
conclude O
that O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
regulates O
nervous B-DNP
and I-DNP
endocrine I-DNP
systems I-DNP
and O
contributes O
to O
the O
improvement O
of O
the O
clinical O
status O
of O
patients O
with O
LSSDS O
. O

-DOCSTART- O

Diabetes B-NEG
Mellitus I-NEG
, I-NEG
Type I-NEG
2 I-NEG

-DOCSTART- O

Promethazine O
hydrochloride O
selectively O
blocks O
peripheral O
H1 O
receptors O
thereby O
diminishing O
the O
effects O
of O
histamine B-DNP
on O
effector O
cells O
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
liver B-NEG
cancer I-NEG
. O

-DOCSTART- O

sores B-NEG
due O
to O
swelling B-NEG
of O
carbuncle B-NEG
. O

-DOCSTART- O

Melanoma B-NEG

-DOCSTART- O

asthma B-NEG
; O

dyspnea B-NEG
; O

abnormal O
rising O
of O
Gi O
; O

upward O
Gi O
dyspnea O
due O
to O
upward O
adverse O
flow O
of O
the O
lung-Gi O

-DOCSTART- O

the O
steaming O
of O
bone O
and O
tidal O
fever B-NEG

-DOCSTART- O

AIDS B-NEG
With O
Tuberculosis B-NEG

-DOCSTART- O

abdominal B-NEG
fullness I-NEG
; O
abdominal B-NEG
distension I-NEG

-DOCSTART- O

fever B-NEG
with O
affection B-NEG
by O
cold B-NEG

-DOCSTART- O

Lopinavir O
inhibits O
the O
HIV B-DNP
viral I-DNP
protease I-DNP
enzyme I-DNP
. O

-DOCSTART- O

Delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O

Treatment O
of O
aching B-NEG
and I-NEG
weakness I-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
, O
asthma B-NEG
and O
cough B-NEG
of O
deficiency-cold O
type O
, O
seminal B-NEU
emission I-NEU
, O
impotence B-NEG
. O

-DOCSTART- O

The O
bactericidal O
action O
of O
dalbavancin O
results O
primarily O
from O
inhibition O
of O
cell-wall O
biosynthesis O
. O

-DOCSTART- O

epilepsy B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Others O
, O
Overall O
CVD O
, O
Diet related O
cardiovascular B-NEG
disease I-NEG
, O
Body B-NEU
weight I-NEU
, O
Evacuation B-NEU
, O
Hemostatic O
function O
. O

-DOCSTART- O

Urinary B-DNP
system I-DNP
health I-DNP
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP

-DOCSTART- O

spinal B-NEG
cord I-NEG
problems I-NEG
, O
pain B-NEG
etc O
. O

-DOCSTART- O

Breech B-NEU
Presentation I-NEU
in O
Pregnancy O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Mimmuietabolic B-NEU
rate I-NEU
/ I-NEU
energy I-NEU
expenditure I-NEU

-DOCSTART- O

profuse B-NEG
metrorrhagia I-NEG

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
effuse O
sweat B-NEU
, O
dissipate O
cold B-NEG
and O
dry O
damp B-NEU
. O

-DOCSTART- O

Colonic B-NEG
Cancer I-NEG
. O

-DOCSTART- O

swelling B-NEG
and O
pain B-NEG
of O
the O
anus O

-DOCSTART- O

sudden O
turmoil B-NEG
; O
cholera B-NEG
disease I-NEG
; O
acute B-NEG
gastroenteritis I-NEG
; O
acute O
vomiting B-NEG
and O
diarrhea B-NEG
a O
group O
of O
diseases O
including O
cholera B-NEG
, O
characterized O
by O
sudden O
and O
drastic O
vomiting B-NEG
and O
diarrhea B-NEG
. O

-DOCSTART- O

invigorate O
blood B-NEU

-DOCSTART- O

Simultaneous O
quantitative O
analyses O
of O
indole O
and O
oxindole O
alkaloids O
of O
Uncaria O
Hook O
in O
rat O
plasma O
and O
brain O
after O
oral O
administration O
of O
the O
traditional O
Japanese O
medicine O
Yokukansan O
using O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
. O

-DOCSTART- O

Woman O
, O
Eye B-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Menopausal B-NEG
woman I-NEG
, O
Eye B-DNP
health I-DNP
, O
Lipid B-NEU
profile I-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
sleep B-NEU
, O
Inflammation B-NEG
, O
Other B-DNP
system I-DNP
health I-DNP
, O
Memory B-POS
, O
Reproductive B-DNP
systems I-DNP
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
post B-NEU
delivery I-NEU
, O
Hypersensitivity B-NEG
, O
Protective B-NEU
immunity I-NEU
, O
Quality O
of O
life O
, O
Eye B-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Blood B-NEU
pressure I-NEU
, O
Protective B-NEU
immunity I-NEU
, O
Diet B-NEG
cardiovascular I-NEG
disease I-NEG
, O
Endocrine B-DNP
system I-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Liver B-DNP
, O
Others O
, O
vigilance B-NEG
, O
Bone B-DNP
Health I-DNP
and O
Osteoporosis B-NEG
, O
Homocysteine B-NEU
metabolism I-NEU
, O
Bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
activation B-POS
, O
attention B-POS
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Liver B-DNP
health I-DNP
, O
Eldery O
, O
Strength B-POS
and O
power B-POS
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Hemostatic B-NEU
function I-NEU
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Intelligence B-POS
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Overall O
CVD B-NEG
, O
General O
woman O
, O
General O
skin B-DNP
health I-DNP
, O
Strength B-POS
and O
power B-DNP
Reproductive I-DNP
systems I-DNP
, O
Arousal B-NEU
, O
Protective B-NEU
immunity I-NEU
, O
Man O
, O
sleep B-NEU

-DOCSTART- O

clear O
the O
liver B-DNP

-DOCSTART- O

Strength B-POS
and O
power B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Mood O

-DOCSTART- O

wind B-NEG
rash I-NEG
; O
German B-NEG
measles I-NEG
; O
rubella B-NEG
; O
urticaria B-NEG

-DOCSTART- O

Rikkunshito O
( O
RKT O
) O
, O
a O
Japanese O
traditional O
medicine O
, O
has O
been O
shown O
to O
stimulate O
food O
intake O
in O
rats O
with O
cisplatin-induced O
anorexia B-NEG
; O
however O
, O
the O
underlying O
mechanisms O
remain O
unknown O
. O

In O
this O
study O
, O
we O
investigated O
whether O
RKT O
is O
involved O
in O
the O
degradation O
of O
peripheral O
ghrelin B-DNP
. O

RKT O
inhibited O
decreases O
in O
plasma B-NEU
ghrelin I-NEU
level I-NEU
and O
enhanced O
acyl- O
to O
desacyl-ghrelin O
( O
A/D O
) O
ratio O
in O
cisplatin-treated O
rats O
. O

Several O
components O
of O
RKT O
demonstrated O
inhibitory O
activity O
against O
ghrelin B-DNP
deacylating I-DNP
enzymes I-DNP
. O

In O
addition O
, O
10-gingerol O
, O
a O
component O
of O
RKT O
, O
inhibited O
exogenous O
ghrelin B-DNP
deacylation I-DNP
. O

Therefore O
, O
RKT O
may O
enhance O
plasma B-NEU
acyl I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
, O
at O
least O
in O
part O
, O
by O
inhibiting O
the O
circulating O
ghrelin B-DNP
degrading I-DNP
enzyme I-DNP
. O

-DOCSTART- O

dispel O
the O
effects O
of O
alcohol O

-DOCSTART- O

stop O
diarrhea B-NEG

-DOCSTART- O

This O
is O
carbuncle B-NEG
and O
cellulites B-NEU
occurred O
on O
the O
back O
. O

-DOCSTART- O

In O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
NF-kB B-NEU
activation I-NEU
and O
apoptotic O
pathways O
. O

-DOCSTART- O

aversion B-NEG
to O
cold O
; O

severe B-NEG
chillness I-NEG
; O

creeping B-NEG
chills I-NEG

-DOCSTART- O

malaria B-NEG
; O
malarial B-NEG
disorder I-NEG
malaria B-NEG
and O
other O
disease O
characterized O
by O
intermittent O
rigor B-NEG
, O
high O
fever B-NEG
and O
sweating B-NEU
. O

-DOCSTART- O

For O
the O
treatment O
of O
cancer B-NEG
patients O
with O
severe O
pain B-NEG
that O
breaks O
through O
their O
regular O
narcotic O
therapy O
. O

-DOCSTART- O

To O
transform O
water O
and O
reduce O
edema B-NEG

-DOCSTART- O

dissipate O
depression B-NEG

-DOCSTART- O

warm O
the O
lumbus B-DNP
and O
knees B-DNP

-DOCSTART- O

Ritonavir O
inhibits O
the O
HIV B-DNP
viral I-DNP
proteinase I-DNP
enzyme I-DNP
which O
prevents O
cleavage O
of O
the O
gag-pol O
polyprotein O
, O
resulting O
in O
noninfectious O
, O
immature O
viral O
particles O
. O

-DOCSTART- O

dry B-NEG
heat I-NEG
and O
cough B-NEG
with O
much O
expectoration B-NEG

-DOCSTART- O

Organic O
iodine O
compounds O
attenuate O
x-rays O
as O
they O
pass O
through O
the O
body O
, O
thereby O
allowing O
the O
body O
structures O
containing O
iodine O
to O
be O
delineated O
in O
contrast O
to O
those O
structures O
that O
do O
not O
contain O
iodine O
. O

The O
degree O
of O
opacity O
produced O
by O
these O
compounds O
is O
directly O
proportional O
to O
the O
total O
amount O
( O
concentration O
and O
volume O
) O
of O
the O
iodinated O
contrast O
agent O
in O
the O
path O
of O
the O
x-rays O
. O

After O
intravascular O
administration O
, O
iodixanol O
makes O
opaque O
those O
internal O
structures O
in O
its O
path O
of O
flow O
, O
allowing O
their O
visualization O
until O
significant O
hemodilution B-NEU
and O
elimination O
occur O
. O

-DOCSTART- O

bloodshot B-NEG
eyes I-NEG
; O
congestion B-NEG
of I-NEG
the I-NEG
eye I-NEG
; O
red B-NEG
eyes I-NEG
; O
redness B-NEG
of I-NEG
the I-NEG
eye I-NEG

-DOCSTART- O

lumbago B-NEG
due O
to O
the O
kidney B-NEG
deficiency I-NEG

-DOCSTART- O

wind B-NEG
invaded O
Chang O
organ O

-DOCSTART- O

Serious O
heat B-NEG
in O
lung O
and O
stomach O
, O
epidemic B-NEG
infectious I-NEG
diseases I-NEG
, O
fever B-NEG
, O
dizziness B-NEG
, O
aching B-NEG
of O
limbs O
, O
cough B-NEG
with O
copious B-NEG
phlegm I-NEG
, O
sore B-NEG
throat I-NEG
, O
epistaxis B-NEG
, O
haemoptysis B-NEG
, O
dryness B-NEG
of I-NEG
mouth I-NEG
and I-NEG
tongue I-NEG
. O

-DOCSTART- O

Lidocaine O
alters O
signal O
conduction O
in O
neurons O
by O
blocking O
the O
fast O
voltage O
gated O
sodium O
( O
Na+ O
) O
channels O
in O
the O
neuronal O
cell O
membrane O
that O
are O
responsible O
for O
signal O
propagation O
. O

-DOCSTART- O

invigorate O
blood B-NEU
and O
move O
stasis B-NEG

-DOCSTART- O

impotence B-NEG

-DOCSTART- O

To O
regulate O
the O
flow O
of O
qi O
in O
the O
chest O
, O
to O
eliminate O
the O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
, O
relieve O
vomiting B-NEG
. O

-DOCSTART- O

Treatment O
of O
cough B-NEG
with O
profuse B-NEG
expectoration I-NEG
, O
indigestion B-NEG
, O
stagnancy B-NEG
of I-NEG
food I-NEG
with O
abdominal B-NEG
pain I-NEG
, O
traumatic B-NEG
swelling I-NEG
and O
ecchymoses B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity I-DNP
intrinsic I-DNP
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl O
, O
APS O
, O
Shc O
and O
Gab O

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-DNP
of I-DNP
downstream I-DNP
signaling I-DNP
molecules I-DNP
including O
PI3 O
kinase O
and O
Akt O
. O

Akt O
regulates O
the O
activity B-DNP
of I-DNP
glucose I-DNP
transporter I-DNP
4 I-DNP
( O
GLUT4 B-DNP
) O
and O
protein B-DNP
kinase I-DNP
C I-DNP
( O
PKC B-DNP
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O

lubricate O
the O
intestines B-DNP

-DOCSTART- O

Infant B-NEG
, I-NEG
Large I-NEG
for I-NEG
Gestational I-NEG
Age I-NEG

-DOCSTART- O

Treatment O
of O
stagnation O
of O
qi O
in O
the O
liver B-DNP
and O
stomach B-DNP
manifested O
by O
distending O
pain B-NEG
in O
the O
chest O
and O
hypochodria B-NEG
, O
fullness B-NEG
and O
stuffiness B-NEG
sensation O
in O
the O
epigastrium O
, O
vomiting B-NEG
and O
belching B-NEG
, O
cough B-NEG
with O
copious O
expectoration B-NEG
. O

-DOCSTART- O

sore B-NEG
; O
pain B-NEG
; O
to O
ache B-NEG

-DOCSTART- O

Heat B-NEG
vexation I-NEG
, O
diabetes B-NEG
mellitus I-NEG
, O
vomiting B-NEG
nausea I-NEG
, O
vacuity B-NEG
heat I-NEG
cough I-NEG
, O
dry O
stool B-NEG
, O
swelling B-NEG
of O
welling B-NEG
abscess I-NEG
, O
welling B-NEG
abscess I-NEG
and O
flat B-NEG
abscess I-NEG
with O
swelling B-NEG
sore I-NEG
. O

-DOCSTART- O

sparrow O
vision O
; O
night B-NEG
blindness I-NEG

-DOCSTART- O

anhidrosis B-NEG
and O
aversion B-NEG
to O
cold O

-DOCSTART- O

Used O
to O
numb O
the O
skin O
, O
or O
surfaces O
of O
the O
penis O
or O
vagina O
, O
in O
preparation O
for O
a O
medical O
procedure O
or O
to O
lessen O
the O
pain B-NEG
of O
inserting O
a O
medical O
instrument O
such O
as O
a O
tube O
or O
speculum O
. O

-DOCSTART- O

Treatment O
of O
jaundice B-NEG
caused O
by O
damp-heat O
, O
heat B-NEG
stroke I-NEG
with O
diarrhea B-NEG
, O
urolithiasis B-NEG
and O
hematuria B-NEG
, O
carbuncles B-NEG
and O
boils B-NEG
, O
traumatic B-NEG
injuries I-NEG
. O

-DOCSTART- O

1 O
To O
clear O
heat B-NEU
and O
toxic B-NEG
material O
, O
deprive O
dampness B-NEU
and O
kill B-POS
parasites I-POS
. O
For O
sorethroat B-NEG
, O
dysentery B-NEG
, O
trichomonas B-NEG
enteritis I-NEG
, O
toothache B-NEG
, O
stomachache B-NEG
and O
leucorrhagia B-NEG
, O
external O
use O
for O
tinea B-NEG
and O
eczema B-NEG
. O
2 O
To O
relieve O
dyspnea B-NEG
and O
cough B-NEG
. O
3 O
Anticarcinogenic B-POS
. O
For O
malignant B-NEG
hydatidiform I-NEG
mole I-NEG
, O
chorionic B-NEG
epithelioma I-NEG
and O
leukemia B-NEG
. O

-DOCSTART- O

1 O
An O
active O
component O
, O
anisaldehyde O
, O
increases O
the O
effect O
of O
streptomycin B-DNP
on O
experimental O
tuberculosis B-NEG
in O
mice O
. O
Accelerating O
gastrointestinal B-NEU
peristalsis I-NEU
, O
and O
promoting O
eliminating B-NEU
of I-NEU
flatus I-NEU
. O
Eliminating O
phlegm B-NEG
. O

-DOCSTART- O

To O
remove O
heat B-NEU
from I-NEU
the I-NEU
lung I-NEU
, O
relieve O
cough B-NEG
and O
resolve O
phlegm B-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
the O
following O
mild-to-moderate O
infections B-NEG
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-NEG
bacterial I-NEG
exacerbations I-NEG
of I-NEG
chronic I-NEG
bronchitis I-NEG
, O
secondary B-NEG
bacterial I-NEG
infection I-NEG
of O
acute B-NEG
bronchitis I-NEG
, O
community B-NEG
- I-NEG
acquired I-NEG
pneumonia I-NEG
, O
pharyngitis B-NEG
/ I-NEG
tonsilitis I-NEG
, O
and O
uncomplicated O
skin B-NEG
and I-NEG
skin I-NEG
structure I-NEG
infections I-NEG
. O

-DOCSTART- O

Atrophic B-NEG
Vaginitis I-NEG

-DOCSTART- O

Its O
chief O
component O
is O
berberine O
. O
1 O
Possessing O
broad-spectrum O
antibacterial B-POS
and O
antiprotozoal B-POS
effects O
. O
2 O
Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-NEG
effect O
on O
experimental O
animals O
. O
3 O
Small O
dosage O
of O
berberine O
enhances O
the O
action O
of O
acetylcholine O
on O
animals' O
hearts B-DNP
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O
4 O
Relaxing O
the O
smooth B-DNP
muscles I-DNP
of O
blood O
vessels O
and O
stimulating O
those O
of O
uterus B-DNP
, O
urinary B-DNP
bladderl I-DNP
bronchus I-DNP
and O
gastrointestines B-DNP
. O
5 O
Promoting O
bile B-NEU
secretion I-NEU
. O
6 O
Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic O
cancer B-NEG
and O
lymphoma B-NEG
. O

-DOCSTART- O

Adult B-NEG
Acute I-NEG
Megakaryoblastic I-NEG
Leukemia I-NEG
( O
M7 B-NEG
) O

-DOCSTART- O

cool O
blood B-NEU

-DOCSTART- O

dysenteric B-NEG
disorder I-NEG
; O

dysentery B-NEG

-DOCSTART- O

absorption O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
motility O

-DOCSTART- O

Dimethindene O
is O
also O
indicated O
for O
pruritus B-NEG
in O
eruptive B-NEG
skin I-NEG
diseases I-NEG
such O
as O
chicken-pox B-NEG
. O

-DOCSTART- O

Asthma B-NEG

-DOCSTART- O

anticancer O

-DOCSTART- O

To O
tonify O
the O
kidney B-DNP

-DOCSTART- O

1 O
To O
relieve O
carbuncle B-NEG
and O
drain B-NEG
pus I-NEG
. O

For O
the O
early O
stage O
of O
carbuncle B-NEG
or O
carbuncle B-NEG
with O
unruptured O
abscess B-NEG
. O

2 O
To O
expel O
wind B-NEG
and O
kill O
parasites B-NEG
. O

For O
tinea B-NEG
infection I-NEG
and O
leprosy B-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Mood O
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Endocrine B-DNP
system I-DNP
, O
Intelligence B-POS
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Inflammation B-NEG
, O
Others O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

Treatment O
of O
impotence O
, O
seminal O
emission O
, O
enuresis O
, O
frequent O
urination B-NEU
, O
aching B-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
with O
cold B-NEG
sensation O
, O
asthma B-NEG
in O
deficiency B-NEG
syndromes I-NEG
of O
the O
kidney O
, O
diarrhea B-NEG
occurring O
before O
dawn O
daily O
. O

-DOCSTART- O

Endocrine B-DNP
system I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP

-DOCSTART- O

hemicrania B-NEG
; O
migraine B-NEG
; O
megrim B-NEG

-DOCSTART- O

severe O
palpitation B-NEG
; O

continuous O
violent O
palpitation B-NEG

-DOCSTART- O

a O
stomachache B-NEG
due O
to O
exhaustion O
of O
vital O
energy O

-DOCSTART- O

Tsumura O
Hachimijiogan O
, O
7.5 O
g O
a O
day O
, O
was O
administered O
to O
30 O
patients O
with O
benign B-NEG
prostatic I-NEG
hypertrophy I-NEG
( O
BPH B-NEG
) O
. O
Clinical O
effects O
were O
estimated O
based O
on O
subjective O
symptoms O
and O
objective O
findings O
obtained O
by O
uroflowmetry O
. O

Twenty O
patients O
( O
0.667 O
) O
showed O
improvement O
of O
subjective O
symptoms O
and O
14 O
patients O
( O
0.467 O
) O
showed O
good O
response O
in O
uroflowmetry O
. O

An O
improvement O
of O
overall O
clinical O
efficacy O
was O
observed O
in O
21 O
patients O
( O
0.7 O
) O

. O
These O
results O
were O
better O
than O
those O
obtained O
with O
5 O
g O
a O
day O
doses O
of O
Tsumura O
Hachimijiogan O
. O

No O
significant O
relation O
between O
the O
Sho O
in O
Chinese O
medicine O
and O
the O
clinical O
effects O
of O
Hachimijiogan O
was O
detected O
. O

No O
side O
effects O
or O
abnormal O
laboratory O
data O
were O
found O
in O
any O
of O
these O
30 O
patients O
. O

-DOCSTART- O

Kampo O
( O
traditional O
Japanese O
herbal O
) O
medicines O
are O
taken O
orally O
due O
to O
which O
the O
gastric O
mucosal O
immune O
system O
may O
act O
as O
one O
of O
the O
major O
targets O
for O
the O
expression O
of O
pharmacological O
activity O
. O

The O
inner O
surface O
of O
the O
intestinal O
tract O
possesses O
a O
large O
area O
of O
mucosal O
membranes O
, O
and O
the O
intestinal O
epithelial O
cells O
sit O
at O
the O
interface O
between O
a O
lumen O
and O
a O
lymphocyte-rich O
lamina O
propria O
. O

The O
cross B-DNP
talk I-DNP
that O
occurs O
between O
these O
compartments O
serves O
to O
maintain O
intestinal O
homeostasis O
, O
and O
the O
cytokine B-DNP
network I-DNP
plays O
an O
important O
role O
in O
the O
cross B-DNP
talk I-DNP
. O

In O
this O
study O
, O
the O
effect O
of O
Hochuekkito O
( O
HET O
) O
, O
one O
of O
Kampo O
medicines O
, O
on O
cytokine B-NEU
secretion I-NEU
of O
intestinal O
epithelial O
cells O
was O
investigated O
. O

When O
murine O
normal O
colonic O
epithelial O
cell-line O
MCE301 B-DNP
cells I-DNP
were O
stimulated O
with O
HET O
, O
the O
contents O
of O
granulocyte B-DNP
colony-stimulating I-DNP
factor I-DNP
( O
G-CSF B-DNP
) O
in O
the O
conditioned O
medium O
were O
significantly O
increased O
in O
dose- O
and O
time-dependent O
manners O
. O

The O
enhanced O
G-CSF B-NEU
gene I-NEU
transcription I-NEU
in O
MCE301 O
cells O
by O
the O
stimulation O
of O
HET O
was O
observed O
by O
RT-PCR O
. O

The O
enhanced O
G-CSF B-NEU
secretion I-NEU
by O
HET O
was O
also O
observed O
in O
C3H/HeJ O
mice-derived O
primary O
cultured O
colonic O
epithelial O
cells O
. O

When O
the O
HET O
was O
fractionated O
, O
only O
the O
polysaccharide O
fraction O
( O
F-5 O
) O
enhanced O
the O
G-CSF B-NEU
secretion I-NEU
of O
MCE301 O
cells O
, O
and O
the O
activity O
of O
F-5 O
lost O
after O
the O
treatment O
of O
periodate O
that O
can O
degrade O
the O
carbohydrate O
moiety O
. O

These O
results O
suggest O
that O
HET O
enhances O
secretion B-NEU
of I-NEU
G-CSF I-NEU
from O
colonic O
epithelial O
cells O
and O
the O
polysaccharide O
is O
one O
of O
the O
active O
ingredients O
of O
HET O
. O

The O
enhanced O
G-CSF B-NEU
secretion I-NEU
by O
HET O
may O
partly O
contribute O
to O
the O
clinically O
observed O
various O
pharmacological O
activities O
of O
HET O
including O
immunomodulating B-NEU
activity I-NEU
. O

-DOCSTART- O

a O
disease O
of O
periumbilical O
sharp O
pain B-NEG
and O
cold B-NEG
hand O
and O
foot O

-DOCSTART- O

Perennial B-NEG
Allergic I-NEG
Rhinitis I-NEG

-DOCSTART- O

Nevirapine O
binds O
directly O
to O
reverse O
transcriptase O
and O
blocks O
the O
RNA-dependent O
and O
DNA-dependent O
DNA O
polymerase O
activities O
by O
causing O
a O
disruption O
of O
the O
enzyme's O
catalytic O
site O
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
diabetes B-NEG
mellitus I-NEG
( O
type O
2 O
) O
. O

-DOCSTART- O

Emtricitabine O
is O
an O
analogue O
of O
cytidine O
. O

The O
drug O
works O
by O
inhibiting O
reverse B-DNP
transcriptase I-DNP
, O
the O
enzyme O
that O
copies O
HIV O
RNA O
into O
new O
viral O
DNA O
. O

By O
interfering O
with O
this O
process O
, O
which O
is O
central O
to O
the O
replication B-NEG
of I-NEG
HIV I-NEG
, O
emtricitabine O
can O
help O
to O
lower O
the O
amount O
of O
HIV B-NEG
, O
or O
viral B-NEG
load I-NEG
. O

Efavirenz O
falls O
in O
the O
NNRTI O
class O
of O
antiretrovirals O
. O

Both O
nucleoside O
and O
non-nucleoside O
RTIs O
inhibit O
the O
same O
target O
, O
the O
reverse B-DNP
transcriptase I-DNP
enzyme I-DNP
, O
an O
essential O
viral B-DNP
enzyme I-DNP
which O
transcribes O
viral O
RNA O
into O
DNA O
. O

-DOCSTART- O

Cyclosporine O
binds O
to O
cyclophilin O
which O
inhibits O
lymphokine B-NEU
production I-NEU
and O
interleukin B-NEU
release I-NEU
, O
shows O
potent O
immunosuppressant O
medication O
. O

-DOCSTART- O

pain B-NEG
and O
swelling B-NEG
of I-NEG
testis I-NEG

-DOCSTART- O

acute B-NEG
arthritis I-NEG
; O
gout B-NEG

-DOCSTART- O

stop O
itching B-NEG

-DOCSTART- O

Metformin O
acts O
by O
the O
initial O
activation O
of O
AMP-activated B-DNP
protein I-DNP
kinase I-DNP
( O
AMPK B-DNP
) O
, O
a O
liver B-DNP
enzyme I-DNP
that O
plays O
an O
important O
role O
in O
insulin O
signaling O
, O
whole O
body B-NEU
energy I-NEU
balance I-NEU
, O
and O
the O
metabolism B-NEU
of I-NEU
glucose I-NEU
and O
fats B-NEG
. O

Sulfonylureas O
such O
as O
glyburide O
bind O
to O
ATP-sensitive B-DNP
potassium I-DNP
channels I-DNP
on O
the O
pancreatic O
cell O
surface O
, O
raising O
intracellular B-NEU
concentrations I-NEU
of I-NEU
calcium I-NEU
ions O
, O
which O
induces O
the O
secretion B-NEU
, O
or O
exocytosis B-NEU
, O
of O
insulin O
. O

-DOCSTART- O

cool O
blood B-NEU
and O
stop O
bleeding B-NEG

-DOCSTART- O

Liver B-NEG
Cirrhosis I-NEG

-DOCSTART- O

To O
supplement O
blood B-DNP
and O
quicken O
blood B-DNP
, O
free O
channels B-DNP
and O
quicken O
network B-DNP
vessels I-DNP
. O

-DOCSTART- O

Intelligence B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Memory B-POS

-DOCSTART- O

swelling B-NEG
and O
pain B-NEG
due O
to O
trauma B-NEG

-DOCSTART- O

Reproductive B-DNP
systems I-DNP
, O
Mood O
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Endocrine B-DNP
system I-DNP
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Memory B-POS
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Quality O
of O
life O
, O
UV B-POS
protection I-POS
, O
Others O
, O
Man O
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Motivation O
, O
Strength B-POS
and O
power B-POS
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
, O
Hemostatic B-DNP
function I-DNP
, O
effort O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Intelligence B-POS
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Overall O
CVD B-NEG
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

( O
1 O
) O
precordial B-NEG
pain I-NEG
; O
intermittent O
cardiac B-NEG
pain I-NEG
( O
2 O
) O
epigastric B-NEG
pain I-NEG

-DOCSTART- O

This O
is O
a O
symptom O
with O
yellow B-DNP
body I-DNP
due O
to O
blood B-NEG
deficiency I-NEG
. O

-DOCSTART- O

Acute B-NEG
otitis I-NEG
media I-NEG
in O
children O
that O
is O
caused O
by O
susceptible O
strains O
of O
Haemophilus B-NEG
influenzae I-NEG
. O

-DOCSTART- O

To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
, O
and O
to O
remove O
the O
retention O
of O
undigested O
food O
. O

-DOCSTART- O

anti-inflammatory B-POS
effects O
of O
the O
Chinese O
herbal O
formula O
FAHF-2 O
in O
experimental O
and O
human O
IBD O
. O

-DOCSTART- O

Wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
swelling B-NEG
pain I-NEG
in I-NEG
throat I-NEG
, O
scrofula B-NEG
, O
mammary B-NEG
welling I-NEG
abscess I-NEG
, O
sore B-NEG
and O
boil B-NEG
, O
eczema B-NEG
, O
innominate B-NEG
toxin I-NEG
swelling I-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

nourish O
blood B-DNP

-DOCSTART- O

fever B-NEG
and O
aversion B-NEG
to O
cold O

-DOCSTART- O

In O
traditional O
Chinese O
medicine O
theory O
( O
TCM O
) O
, O
the O
affected O
parts O
of O
sprains B-NEG
, O
bruises B-NEG
and O
arthritis B-NEG
are O
considered O
to O
be O
under O
certain O
conditions O
of O
TCM O
concept O
. O

We O
administered O
two O
Kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery B-POS
from O
these O
conditions O
. O

Jidabokuippo O
( O
Zhidapuyifang O
in O
Chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' O
is O
expected O
to O
remove O
these O
conditions O
. O

Hachimijiogan O
( O
Baweidihuangwan O
in O
Chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
Rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone O
injury O
and O
regulates O
bone B-NEU
metabolism I-NEU
by O
changing O
such O
conditions O
based O
on O
TCM O
theory O
. O

We O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-NEG
, O
sprains B-NEG
, O
arthritis B-NEG
and O
spinal B-NEG
compression I-NEG
fracture I-NEG
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

Patients O
reported O
on O
changes O
in O
the O
pain B-NEG
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
VAS O
) O
before O
and O
after O
administration O
of O
Kampo O
medicine O
. O

In O
almost O
all O
cases O
, O
recovery B-POS
began O
promptly O
after O
administration O
and O
the O
pain B-NEG
disappeared O
within O
approximately O
2 O
weeks O
. O

Large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-POS
than O
small O
doses O
. O

Administration O
of O
a O
combination O
of O
two O
Kampo O
medicines O
, O
Jidabokuippo O
and O
Hachimijiogan O
, O
quickly O
resolved O
the O
pain B-NEG
of O
bruises B-NEG
, O
sprains B-NEG
, O
arthritis B-NEG
and O
one O
spinal B-NEG
compression I-NEG
fracture I-NEG
. O

-DOCSTART- O

Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
has O
been O
used O
to O
cure O
neuropsychological B-NEG
disorders I-NEG
. O

In O
the O
present O
study O
, O
the O
effect O
of O
Yokukansan O
on O
social B-NEG
isolation-induced I-NEG
- I-NEG
induced I-NEG
aggressive I-NEG
behavior I-NEG
was O
examined O
in O
zinc-deficient O
mice O
, O
which O
were O
fed O
a O
zinc-deficient O
diet O
and O
a O
drinking O
water O
containing O
Yokukansan O
for O
2 O
weeks O
. O

In O
the O
resident-intruder O
test O
, O
the O
rate O
of O
mice O
that O
exhibited O
aggressive B-NEG
behavior I-NEG
in O
zinc-deficient O
mice O
, O
which O
was O
significantly O
higher O
than O
that O
in O
the O
control O
mice O
, O
was O
significantly O
decreased O
by O
administration O
of O
Yokukansan O
. O

The O
basal O
level O
of O
serum B-DNP
glucocorticoid I-DNP
, O
which O
was O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
was O
lowered O
by O
administration O
of O
Yokukansan O
. O

On O
the O
other O
hand O
, O
serum B-NEU
glucocorticoid I-NEU
levels I-NEU
after O
the O
resident-intruder O
test O
were O
almost O
the O
same O
between O
the O
control O
and O
zinc-deficient O
mice O
. O

However O
, O
administration O
of O
Yokukansan O
to O
zinc-deficient O
mice O
significantly O
increased O
serum B-NEU
glucocorticoid I-NEU
level I-NEU
after O
the O
resident-intruder O
test O
and O
the O
significant O
difference O
in O
the O
rate O
of O
serum B-DNP
corticosterone I-DNP
level I-DNP
after O
the O
test O
to O
the O
basal O
level O
between O
the O
control O
and O
zinc-deficient O
mice O
was O
abolished O
. O

Dietary O
zinc O
deficiency O
increases O
the O
basal O
levels B-NEU
of I-NEU
serum I-NEU
glucocorticoid I-NEU
, O
while O
may O
insufficiently O
increase O
serum B-NEU
glucocorticoid I-NEU
levels I-NEU
in O
the O
resident-intruder O
test O
. O

The O
concentrations O
of O
glutamate B-DNP
and O
GABA B-DNP
( O
y-aminobutyric B-DNP
acid I-DNP
) O
in O
the O
brain O
were O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
while O
Yokukansan O
ameliorated O
the O
significant O
increases O
. O

These O
results O
indicate O
that O
Yokukansan O
ameliorates O
social O
isolation-induced O
aggressive B-NEG
behavior I-NEG
of O
zinc-deficient O
mice O
, O
probably O
via O
amelioration O
of O
abnormal O
glucocorticoid B-DNP
secretion O
. O

The O
ameliorative O
effect O
seems O
to O
be O
linked O
to O
the O
modification O
of O
glutamatergic O
neuron B-NEU
activity I-NEU
after O
administration O
of O
Yokukansan O
. O

-DOCSTART- O

To O
dispel O
wind-heat B-NEU
, O
to O
subdue O
hyperactivity B-NEG
of I-NEG
the I-NEG
liver I-NEG
, O
and O
improve O
eyesight B-POS
. O

-DOCSTART- O

This O
is O
insanity B-NEG
caused O
by O
hurt O
of O
mind O
due O
to O
vexation B-NEG
and O
stuffiness B-NEG
. O

-DOCSTART- O

vomiting B-NEG
and O
diarrhea B-NEG

-DOCSTART- O

Bone B-NEU
Health I-NEU
and O
Osteoporosis B-NEG
, O
Woman O
, O
Bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

Asthma B-NEG
, O
chronic B-NEG
bronchitis I-NEG
, O
stomachache B-NEG
, O
wind-damp B-NEG
pain I-NEG
, O
scrofula B-NEG
, O
cold B-NEG
suppurative I-NEG
sore I-NEG
, O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

Ephedrine O
is O
a O
sympathomimetic O
amine O
- O
that O
is O
, O
its O
principal O
mechanism O
of O
action O
relies O
on O
its O
direct O
and O
indirect O
actions O
on O
the O
adrenergic O
receptor O
system O
, O
which O
is O
part O
of O
the O
sympathetic O
nervous O
system O
. O

Ephedrine O
increases O
post-synaptic B-NEU
noradrenergic I-NEU
receptor I-NEU
activity I-NEU
by O
( O
weakly O
) O
directly O
activating O
post-synaptic B-DNP
receptors I-DNP
and O
receptors O
, O
but O
the O
bulk O
of O
its O
effect O
comes O
from O
the O
pre-synaptic O
neuron O
being O
unable O
to O
distinguish O
between O
real O
adrenaline O
or O
noradrenaline O
from O
ephedrine O
. O

The O
ephedrine O
, O
mixed O
with O
noradrenaline O
, O
is O
transported O
through O
the O
noradrenaline O
reuptake O
complex O
and O
packaged O
( O
along O
with O
real O
noradrenaline O
) O
into O
vesicles O
that O
reside O
at O
the O
terminal O
button O
of O
a O
nerve O
cell O
. O

Ephedrine's O
action O
as O
an O
agonist O
at O
most O
major O
noradrenaline O
receptors O
and O
its O
ability O
to O
increase O
the O
release O
of O
both O
dopamine O
and O
to O
a O
lesser O
extent O
, O
serotonin O
by O
the O
same O
mechanism O
is O
presumed O
to O
have O
a O
major O
role O
in O
its O
mechanism O
of O
action O
. O

-DOCSTART- O

settle O
the O
pain B-NEG
and O
tranquilize O

-DOCSTART- O

Ureteral B-NEG
Stent I-NEG
Occlusion I-NEG

-DOCSTART- O

Pulmonary B-NEG
Disease I-NEG
, I-NEG
Chronic I-NEG
Obstructive I-NEG

-DOCSTART- O

expel O
worm B-NEG

-DOCSTART- O

vomiting B-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
engender O
liquid O
, O
moisten O
dryness B-NEG
and O
harmonize O
center O
, O
resolve O
toxin B-NEG
. O

-DOCSTART- O

uncomfortable O
of O
the O
heart B-DNP
and O
gallbladder B-DNP

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
C I-NEG

-DOCSTART- O

urinary B-NEG
incontinence I-NEG
; O
galacturia B-NEG
; O
stranguria B-NEG
with I-NEG
chyluria I-NEG
; O
stranguria B-NEG
marked O
by O
chyluria B-NEG

-DOCSTART- O

Non B-NEG
Small I-NEG
Cell I-NEG
Lung I-NEG
Carcinoma I-NEG

-DOCSTART- O

HIV B-NEG
Infections I-NEG

-DOCSTART- O

pulmonary B-NEG
asthenia I-NEG
; O
lung B-NEG
atropy I-NEG
; O
pulmonary B-NEG
flaccidity I-NEG
syndrome I-NEG

-DOCSTART- O

Filgrastim O
binds O
to O
the O
G-CSF O
receptor O
and O
stimulates O
the O
production B-NEU
of I-NEU
neutrophils I-NEU
in O
the O
bone O
marrow O
. O

-DOCSTART- O

a O
mass O
amount O
of O
phlegm B-NEG
, O
and O
dyspnea B-NEG
and O
cough B-NEG

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
quicken O
blood B-DNP
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

To O
drain O
accumulated O
cold B-NEG
downward O

-DOCSTART- O

Otitis B-NEG
Media I-NEG

-DOCSTART- O

cosolidate O
bones B-DNP

-DOCSTART- O

Metformin O
acts O
by O
the O
initial O
activation B-DNP
of I-DNP
AMP-activated I-DNP
protein I-DNP
kinase I-DNP
( O
AMPK O
) O
, O
a O
liver O
enzyme O
that O
plays O
an O
important O
role O
in O
insulin B-NEU
signaling I-NEU
, O
whole B-NEU
body I-NEU
energy I-NEU
balance I-NEU
, O
and O
the O
metabolism B-NEU
of I-NEU
glucose I-NEU
and I-NEU
fats I-NEU
. O

Pioglitazone O
activates O
peroxisome B-DNP
proliferator-activated I-DNP
receptor I-DNP
gamma I-DNP
( O
PPAR-gamma B-DNP
) O
, O
a O
ligand-activated B-DNP
transcription I-DNP
factor I-DNP
, O
thereby O
inducing O
cell B-NEU
differentiation I-NEU
and O
inhibiting O
cell B-NEU
growth I-NEU
and O
angiogenesis B-NEU
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
powerlessness B-NEG
in O
a O
waist O
and O
knee O
. O

-DOCSTART- O

dyspnea B-NEG
due O
to O
the O
kidney B-NEG
deficiency I-NEG

-DOCSTART- O

Adult B-NEG
Acute I-NEG
Lymphocytic I-NEG
Leukemia I-NEG

-DOCSTART- O

refers O
to O
the O
dream-disturbed O
sleep O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
motility B-NEU
, O
Others O

-DOCSTART- O

Since O
it O
is O
not O
degraded O
in O
the O
neuromuscular O
junction O
, O
the O
depolarized O
membrance O
remains O
depolarized O
and O
unresponsive O
to O
any O
other O
impulse O
, O
causing O
muscle B-NEG
paralysis I-NEG
. O

-DOCSTART- O

clear O
the O
heart B-DNP
and O
relieve O
vexation B-NEG

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Liver B-DNP

-DOCSTART- O

( O
1 O
) O
/ O
/ O
morbid O
leukorrhea B-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases(in I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

HIV-1 B-NEG
Infections I-NEG

-DOCSTART- O

sore B-NEG
throat I-NEG
; O
swollen B-NEG
and O
pailful B-NEG
throat O

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
taxation O
damage O
in O
lumbar B-DNP
muscle I-DNP
, O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
pricking B-NEG
pain I-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

metrorrhagia B-NEG
and O
bloody B-NEG
stool I-NEG

-DOCSTART- O

For O
tonifying O
weakness O

-DOCSTART- O

Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness B-NEG
and O
fullness B-NEG
sensation O
in O
the O
abdomen O
with O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
damp-heat B-NEU
in O
combination O
with O
cold B-NEG
. O

-DOCSTART- O

Treament O
of O
spitting B-NEG
of I-NEG
blood I-NEG
, O
epistaxis B-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
, O
amenorrhea B-NEG
with O
blood O
stasis O
, O
arthralgia B-NEG
, O
traumatic O
swelling B-NEG
and O
pain B-NEG
. O

-DOCSTART- O

To O
dissipate O
binds B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Body B-NEG
fat I-NEG
deposition I-NEG
( O
total O
amount O

-DOCSTART- O

To O
eliminate O
phlegm B-NEG
( O
Powder O
insufflation O
for O
pharyngitis B-NEG
and O
diphtheria B-NEG
) O
. O

-DOCSTART- O

Phenylpropanolamine O
acts O
directly O
on O
alpha- O
and O
, O
to O
a O
lesser O
degree O
, O
beta-adrenergic O
receptors O
in O
the O
mucosa O
of O
the O
respiratory O
tract O
. O

-DOCSTART- O

insomnia B-NEG

-DOCSTART- O

Treatment O
of O
deficiency B-NEG
syndrome I-NEG
of O
the O
kidney O
marked O
by O
back B-NEG
pain I-NEG
, O
tinnitus B-NEG
, O
impairment B-NEG
of I-NEG
hearing I-NEG
and O
looseness B-NEG
of I-NEG
teeth I-NEG
, O
traumatic B-NEG
injury I-NEG
, O
bone B-NEG
fracture I-NEG
, O
external O
use O
for O
alopecia B-NEG
areata I-NEG
, O
vitiligo B-NEG
. O

-DOCSTART- O

Pancreatic B-NEG
cancer I-NEG

-DOCSTART- O

Gout B-NEG

-DOCSTART- O

Hochuekkito O
, O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
and O
its O
Polysaccharide O
Portion O
Stimulate O
G-CSF O
Secretion O
from O
Intestinal O
Epithelial O
Cells O
. O

-DOCSTART- O

the O
symptom O
caused O
by O
stagnation O
of O
phlegm-heat B-NEG

-DOCSTART- O

For O
malaria B-NEG
, O
applying O
crushed O
product O
on O
Neiguan O
( O
P.6 O
) O
and O
Dazhui O
( O
Du' O
14 O
) O
2 O
hours O
before O
the O
episode O
; O
alos O
used O
for O
dyspnea B-NEG
due O
to O
the O
retention O
of O
phlegm B-NEG
. O

-DOCSTART- O

mania-withdrawal B-NEG
; O

mania B-NEG
; O

manic-depressive B-NEG
psychosis I-NEG

-DOCSTART- O

1 O
For O
cases O
with O
paralysis B-NEG
of I-NEG
lower I-NEG
limbs I-NEG
and O
feverish B-NEG
sensation I-NEG
of O
joints,which O
are O
attritbutive O
to O
deficiency O
of O
kidney-yin,omit O
menthae,Ziziphi O
jujubae O
and O
add O
carapax O
trionycis O
and O
ramulus O
mori O
to O
benefit O
kidney-yin O
and O
eliminate O
asthenic O
heat O
. O

-DOCSTART- O

all O
kinds O
of O
disease O
due O
to O
wind B-NEG

-DOCSTART- O

End B-NEG
Stage I-NEG
Renal I-NEG
Disease I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Fat B-NEU
storage I-NEU
and O
oxidation O

-DOCSTART- O

Promoting O
bile B-NEU
secretion I-NEU
. O

-DOCSTART- O

Lenalidomide O
inhibits O
TNF-alpha B-NEU
production I-NEU
, O
stimulates O
T B-DNP
cells I-DNP
, O
reduces O
serum B-NEU
levels I-NEU
of I-NEU
the I-NEU
cytokines I-NEU
vascular I-NEU
endothelial I-NEU
growth I-NEU
factor I-NEU
( O
VEGF B-NEU
) O
and O
basic O
fibroblast B-DNP
growth I-DNP
factor I-DNP
( O
bFGF O
) O
, O
and O
inhibits O
angiogenesis B-NEU
. O

-DOCSTART- O

thirst B-NEG

-DOCSTART- O

To O
relax O
the O
bowels B-NEG
, O
and O
to O
cause O
diuresis B-NEG
. O

-DOCSTART- O

redness B-NEG
, O
swelling B-NEG
and O
pain B-NEG
of O
the O
eyes O

-DOCSTART- O

excessive O
drinking O
of O
water O
due O
to O
thirst B-NEU

-DOCSTART- O

Leukemia B-NEG

-DOCSTART- O

severe O
palpitation B-NEG
; O
continuous O
violent O
palpitation B-NEG

-DOCSTART- O

unblock O
blood B-DNP

-DOCSTART- O

five O
colored O
dysentery B-NEG
; O
dysentery B-NEG
with O
multi-colored O
stools B-NEG

-DOCSTART- O

Coronary O
Artery O
Bypass O
Graft O
Redo O

-DOCSTART- O

aversion B-NEG
to I-NEG
heat I-NEG
during O
fever B-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
resolve O
toxin B-NEG
, O
dry O
damp B-NEU
and O
kill O
worms B-NEG
. O

-DOCSTART- O

acute B-NEG
appendicitis I-NEG
; O
periappendicular O
abscess B-NEG
; O
intestinal O
carbuncle B-NEG
; O
intestinal O
abscess B-NEG

-DOCSTART- O

Not O
discarded O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG

-DOCSTART- O

chest O
and O
hypochondriac O
pain O

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
HIV B-NEG
infection I-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
rheumatoid B-NEG
arthritis I-NEG
( O
RA B-NEG
) O
. O

-DOCSTART- O

Lymphoma B-NEG
, I-NEG
Non-Hodgkin I-NEG

-DOCSTART- O

Quality O
of O
life O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Mood O

-DOCSTART- O

fever B-NEG
with O
dysphoria B-NEG
; O
dysphoria B-NEG
with O
smothery O
sensation B-NEG
; O
smothery O
fever B-NEG

-DOCSTART- O

Circulating O
Tumor B-DNP
Cells I-DNP
in O
Pancreatic O
Cancer O
Surgery O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
colorectal B-NEG
cancer I-NEG
. O

-DOCSTART- O

night B-NEU
sweat I-NEU
; O

night B-NEU
sweating I-NEU
spontaneous O
sweating B-NEU
during O
asleep O
and O
no B-NEU
sweating I-NEU
while O
awake O
, O
chiefly O
caused O
by O
deficiency O
of O
vital O
essence O
and O
presence O
of O
internal B-NEU
heat I-NEU
. O

-DOCSTART- O

morbid B-NEG
leukorrhea I-NEG
; O

gynecological B-NEG
diseases I-NEG
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O

The O
hormones O
, O
T O
4 O
and O
T O
3, O
are O
tyrosine-based O
hormones O
produced O
by O
the O
thyroid O
gland O
. O

Iodine O
is O
an O
important O
component O
in O
their O
synthesis O
. O

The O
major O
secreted O
form O
of O
thyroid O
hormone O
is O
T4 O
. O

T4 O
is O
converted O
T3 O
, O
the O
more O
active O
thyroid O
hormone O
, O
by O
deiodinases O
in O
peripheral O
tissues O
. O

T3 O
acts O
in O
the O
body O
to O
increase O
basal B-NEU
metabolic I-NEU
rate I-NEU
, O
alter O
protein B-NEU
synthesis I-NEU
and O
increase O
the O
body's B-NEU
sensitivity I-NEU
to O
catecholamines O
( O
such O
as O
adrenaline O
) O
. O

Thyroid O
hormones O
are O
essential O
for O
proper O
development O
and O
differentiation O
of O
all O
cells O
of O
the O
human O
body O
. O

T O
4 O
and O
T O
3 O
regulate O
protein O
, O
fat O
and O
carbohydrate O
metabolism O
to O
varying O
extents O
. O

The O
most O
pronounced O
effect O
of O
the O
hormones O
is O
in O
altering O
how O
human O
cells O
use O
energetic O
compounds O
. O

The O
thyroid O
hormone O
derivatives O
bind O
to O
the O
thyroid O
hormone O
receptors O
initially O
to O
initiate O
their O
downstream B-NEU
effects I-NEU
. O

-DOCSTART- O

( O
1 O
) O
/ O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

Treatment O
of O
dry B-NEG
cough I-NEG
caused O
by O
heat B-NEU
in I-NEU
the I-NEU
lung I-NEU
, O
bloody B-NEG
sputum I-NEG
in O
phthisis B-NEG
, O
thirst B-NEU
in O
febrile B-NEG
diseases I-NEG
. O

-DOCSTART- O

terminate O
delivery O

-DOCSTART- O

Neurological B-DNP
systems I-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Memory B-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Hemostatic B-DNP
function I-DNP
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

( O
1 O
) O
tangling O
up O
of O
intestine O
; O
accumulation O
of O
pathogenic O
factor O
in O
viscera O
( O
2 O
) O
Accumulation O
of O
Eum O
Cold B-NEG
in O
Viscera O
one O
of O
the O
symptoms O
in O
Soeumin O
( O
marked O
by O
hard O
mass O
on O
the O
right O
side O
of O
the O
epigastrium O
. O
The O
prognosis O
is O
not O
hopeful O
. O

-DOCSTART- O

Its O
solution O
may O
kill O
the O
oncomelania O
. O

-DOCSTART- O

ascites B-NEG
; O
abdominal B-NEG
distention I-NEG
due O
to O
accumulation O
of O
liquid B-NEU

-DOCSTART- O

menstrual B-NEG
irregularities I-NEG
; O
menstrual B-NEG
disorders I-NEG
; O
abnormal B-NEG
menstruation I-NEG

-DOCSTART- O

Neurological B-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Protective B-NEU
immunity I-NEU
, O
Others O

-DOCSTART- O

SR O
58611 O
has O
positive B-NEU
chronotropic I-NEU
effect I-NEU
which O
is O
mainly O
of O
peripheral O
origin O
and O
can O
be O
attributed O
to O
a O
baroreceptor-mediated B-NEU
reflex I-NEU
due O
to O
the O
beta3-adrenoceptor B-NEU
mediated I-NEU
vasodilation I-NEU
with O
an O
increase O
in O
sympathetic B-NEU
tone I-NEU
and O
a O
reduction O
in O
vagal B-NEU
tone I-NEU
to O
the O
heart O
. O

-DOCSTART- O

Deficiency O
of O
both O
qi O
and O
blood B-NEU
marked O
by O
pallor B-NEG
, O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cardiac B-NEG
palpitation I-NEG
, O
dizziness B-NEG
, O
spontaneous B-NEU
sweating I-NEU
, O
lassitude B-NEG
and O
cold B-NEG
extremities O
, O
or O
excessive B-NEG
menstrual I-NEG
discharge I-NEG
. O

-DOCSTART- O

stop O
dysentery B-NEG

-DOCSTART- O

Diarrhea B-NEG
, O
Malnutrition B-NEG

-DOCSTART- O

pain B-NEG
from O
cramped O
tendons O
and O
bones O

-DOCSTART- O

Treatment O
of O
taeniasis B-NEG
, O
ancylostomiasis B-NEG
, O
ascariasis B-NEG
, O
intestinal B-NEG
parasitosis I-NEG
with O
abdominal B-NEG
pain I-NEG
or O
with O
infantile B-NEG
malnutrition I-NEG
. O

-DOCSTART- O

lack O
of O
essence O
and O
blood B-DNP

-DOCSTART- O

damp B-NEU
Pi O
arthritis B-NEG
due O
to O
dampness B-NEU
. O

damp B-NEG
stroke I-NEG
; O

attack O
of O
dampness B-NEU
syndrome O
due O
to O
attack O
of O
pathogenic B-NEG
factors I-NEG
. O

-DOCSTART- O

Trachoma B-NEG

-DOCSTART- O

wind B-NEG
stroke I-NEG

apoplexy B-NEG

invasion B-NEG
of I-NEG
wind I-NEG
pathogen I-NEG

wind-stroke B-NEG
syndrome I-NEG
syndrome O
due O
to O
external O
affection O
by O
the O
pathogenic B-NEG
wind I-NEG
, O
manifested O
by O
fever B-NEG
, O
headache B-NEG
, O
perspiration B-NEG
, O
slow O
and O
floating O
pulse B-DNP
. O

-DOCSTART- O

After O
binding O
to O
HER2 O
on O
the O
tumor O
cell O
surface O
, O
trastuzumab O
induces O
an O
antibody-dependent B-NEG
cell-mediated I-NEG
cytotoxicity I-NEG
against O
tumor B-DNP
cells I-DNP
that O
overexpress O
HER2 O
. O

Epirubicin O
intercalates O
into O
DNA O
and O
interacts O
with O
topoisomerase B-DNP
II I-DNP
, O
thereby O
inhibiting O
DNA B-NEU
replication I-NEU
and O
repair O
and O
RNA O
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

Infection B-NEG
of O
upper O
respiratory O
tract O
, O
pneumonia B-NEG
, O
acute B-NEG
gastroenteritis I-NEG
, O
dysentery B-NEG
, O
sore B-NEG
and O
boil B-NEG
, O
scab B-NEG
and O
lichen B-NEG
, O
eczema B-NEG
, O
burns B-NEG
and O
scalds B-NEG
, O
infection B-NEG
of O
biliary O
tract O
, O
poisonous B-NEG
insect I-NEG
stings I-NEG
. O

-DOCSTART- O

Glaucoma B-NEG
, O
Open-angle O

-DOCSTART- O

furuncle B-NEG
and O
swelling B-NEG
of O
carbuncle B-NEG

-DOCSTART- O

A O
symptom O
that O
the O
chest O
and O
a O
middle O
part O
of O
the O
stomach O
are O
full O
and O
uncomfortable O
. O

-DOCSTART- O

